Renovorx, Inc. · NASDAQ:RNXT
Renovorx — Q1 2026 Earnings Presentation
30 slides from Renovorx's earnings presentation, May 14, 2026
Slide 1: Investor Presentation
Investor Presentation NASDAQ | RNXT Delivering therapy where it matters® May 2026 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, i
Slide 3: Advancing adoption of FDA-cleared RenovoCath at U.S. Cancer Centers, strengthening commercial momentum
• As of February 27, 2026, 12 U.S. cancer centers utilizing RenovoCath repeatedly; 21 additional centers Advancing adoption of FDA-cleared evaluating the device, have completed evaluation, or preparing for activation. These 33 centers represent tripling of near-term pipeline compared to first quarte
Slide 4: Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform
Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform Enabled by RenovoCath 3 NASDAQ | RNXT
Slide 5: Addressing a Significant Problem in Cancer Treatment
Addressing a Significant Problem in Cancer Treatment Hypervascular tumors are inadequately treated with current Hypovascular tumors = major barrier to chemotherapy treatment therapies success For example, liver tumors are highly vascularized Many tumors, like pancreatic tumors, have poor blood suppl
Slide 6: TAMP Improves a Drug's Therapeutic Index
TAMP Improves a Drug’s Therapeutic Index Increases Drug Concentration to Reduces Drug AUC0-t by 43.5% Compared to IV Target Pathological Site by ~100X1 Administration2 Tissue Concentration Gem. (ng/g) Drug Exposure IA vs. IV route 10^6 15 Gemcitabine AUC0-t (h*mcg/mL) 10^5 10 10^4 10^3 5 10^2 0 10^1
Slide 7: Illustration of TAMP with RenovoCath
6 Illustration of TAMP with NASDAQ | RNXT RenovoCath
Slide 8: Mechanism: Trans-Arterial Micro-Perfusion (TAMP)
Mechanism: Trans-Arterial Micro-Perfusion (TAMP) Mechanism: after vessel isolation, increase in pressure forces drug across the artery wall into the micro-vasculature and into tissue At optimal pressure – tissue pressure is overcome, forcing delivery outside the 70 primary vessel into the tissue 60
Slide 9: Patient and Physician Experience
Patient and Physician Experience RenovoCath Other Treatment Options RenovoCath Patient Experience Other Patient Experience ▪ ~8 treatments over 4 months (2x/month hospital visits) with ▪ Traditional systemic gemcitabine + Abraxane: 12 hospital/clinic visits over disposable device (no implant) 4-mont
Slide 10: Physicians Have Expressed Interest in RenovoCath Across a Broad Market
Physicians Have Expressed Interest in RenovoCath Across a Broad Market 200000 NEW ANNUAL CASES (U.S.) All Cases Cases with RenovoCath 160000 120000 80000 40000 0 PANCREATIC1 LAPC2 CCA3 eCCA4 LUNG NSCLC GLIOMA7 GLIOBLASTOMA8 Sarcomas11 UTERINE9 TACE ELIGIBLE (NSCLC)5 STAGE 36 UTERINE10 1 https://seer
Slide 11: Commercial Opportunity: RenovoCath Standalone, FDA-Cleared Drug-Delivery Device
Commercial Opportunity RenovoCath Standalone, FDA-Cleared Drug-Delivery Device 10 NASDAQ | RNXT
Slide 12: Potential High Margin, Large Market Opportunity for RenovoCath Device Alone
Potential High Margin, Large Market Opportunity for RenovoCath Device Alone RenovoCath Market Opportunity Analogous pressure-mediated delivery catheter ASPs $6k-$8.5k/unit1 As of 2025, areas of expressed near-term interest by physicians in the U.S. Annual average procedures 5-6 per patient2 ▪ ~67k p
Slide 13: RenovoCath Go-to-Market Strategy
RenovoCath Go-to-Market Strategy 2025 Limited Market Launch (without recently established commercial team) Builds Foundation for 2026 Commercialization Ramp and Revenue Growth RenovoCath potential high-volume centers1 Go-To-Market Strategy • Broadening adoption momentum: Customer pipeline continues
Slide 14: RenovoCath Commercialization Update (as of 02/27/26)
RenovoCath Commercialization Update (as of 02/27/26) 2025 Commercial Exploration Laid Foundation for 2026 Revenue Growth and Commercialization RenovoCath customers actively treating patients: 12 cancer centers Pipeline expansion: 33 total engaged centers + interest from additional U.S. RenovoCath Cu
Slide 15: Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
Pivotal Phase III TIGeR-PaC Clinical Trial (NCT03257033) in Locally Advanced Pancreatic Cancer (LAPC) 14 NASDAQ | RNXT
Slide 16: Significant Unmet Need
Significant Unmet Need Three FDA approvals in the last 10 years showed minimal Median Overall Survival (OS) benefit and increased toxicity1 Gemcitabine + Abraxane Abraxane 38% Grade 3 Abraxane obtained FDA approval in 2013 on a or Higher Neutropenia and 7-week Median Overall Survival (OS) benefit2 1
Slide 17: Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC
Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC Independent interviews suggest oncologists likely to adopt gemcitabine delivered via RenovoCath w/ at least 3–4-month OS benefit and toxicity improvement are met 5 Number of Respondents 4 3 2 1 0 <1 1 month 2 months 3 months 4 mont
Slide 18: RR3 TIGeR-PaC Phase III Randomized Trial
RR3 TIGeR-PaC Phase III Randomized Trial Combination product trial for TAMP Delivery of Intra-Arterial (IA) Gemcitabine (IAG) via FDA-Cleared RenovoCath in Locally Advanced Pancreatic Cancer Induction Phase 1:1 RANDOMIZATION PHASE 1◦ Endpoint 4-Month treatment protocol: standard of care IV (systemic
Slide 19: Statistics and Trial Status
Statistics and Trial Status Incremental Significance Level Percent of Final Analysis Total Number of Observed Events (Deaths) to Interim Analysis at time of Events Trigger Analysis Interim Analysis First 30% 26 0.0001 Second 60% 52 0.008 Final 100% 86 0.048 Statistical Design Enrollment Status Pre-P
Slide 20: TAMP (IA gemcitabine): 6-month Median OS Benefit vs. IV gemcitabine + Abraxane
TAMP (IA gemcitabine): 6-month Median OS Benefit vs. IV (systemic) gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis Data on 45 patients randomized INDUCTION RANDOMIZED TREATMENT & FOLLOW-UP s • 23 randomized to RenovoCath plus Gemcitabine • 22 randomized to IV gemcitabine + Abraxane
Slide 21: TAMP (IA Gem): Fewer AEs and SAEs vs IV gemcitabine + Abraxane
TAMP (IA Gem): Fewer AEs and SAEs vs IV (systemic) gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis) 65% fewer total AEs and SAEs Fewer AEs in 11/13 categories with greater than 10% frequency in IA vs. IV arm in each arm (All Grades) 300 Adverse Events IV Gem + Pac IA Gem Neutropeni
Slide 22: Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials
Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials (IIT) Evidence-Based Growth Strategy – RR5 Clinical and Strategic Advancement – RR5 Objective First Registry-Eligible Patient ▪ Expand safety and performance data of RenovoCath and its Procedure Successfully Completed ass
Slide 23: Experienced Management Team
Experienced Management Team Shaun R. Bagai Richard Stark Chief Executive Officer & Board Member Commercial Advisor Consultant 2 ▪ HeartFlow (>$2B IPO) ▪ Innoblative Designs ▪ Ardian (Acquired for > $900M) ▪ AngioDynamics ▪ Medtronic Vascular ▪ TransVascular (Acquired by Medtronic) Ramtin Agah, MD Ro
Slide 24: Board of Directors
Board of Directors Ramtin Agah, MD Laurence J. Marton, MD Executive Chairman, Chief Medical Officer, & Founder Director ▪ Interventional Cardiology, El Camino Hospital ▪ Board: Cellsonics, TOMA Biosciences, xCures ▪ Consultant, Abbott Vascular Shaun R. Bagai Una S. Ryan, PhD, OBE Director & Chief Ex
Slide 25: Scientific Advisory Board
Scientific Advisory Board Timothy Donahue, MD Karyn A. Goodman, MD, MS ▪ Director of the UCLA Agi Hirshberg Center for Pancreatic ▪ Professor and Vice Chair of Clinical Research, Department of Diseases Radiation Oncology, Icahn School of Medicine at Mount Sinai ▪ Garry Shandling Chair in Pancreatic
Slide 26: RenovoCath Medical Advisory Board
RenovoCath Medical Advisory Board Nadine Abi-Jaoudeh, MD Mustafa Al-Roubaie, MD ▪ Chief of Interventional Radiology and Director of Clinical ▪ Interventional Radiologist at Moffitt Cancer Center Research in the Department of Radiology at the ▪ Associate Professor of Radiology and Oncologic Sciences
Slide 27: Upcoming Milestones
Upcoming Milestones 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 RenovoCath Generates Completion of $1.1 Million in 2025 TIGeR-PaC Revenue Trial Enrollment RenovoRxinReports First Full Final human PK Year of by Middle of 2026 Q1-Q3 RenovoCath data supporting Commercialization Revenues of ~$900K with RenovoRx Named t
Slide 28: 2025 Financial Highlights
2025 Financial Highlights RNXT (USD) Daily Performance – since 9/30/25 1.40 FY 2025 Revenue: Over $1 Million𝟏 without dedicated sales & marketing infrastructure 1.30 $1.10 Close on March 25 ▪ Establishment of focused and agile commercial team in late 2025 1.20 1.10 Cash: $13.0 Million𝟏 ▪ Lower…
Slide 29: How Hospitals are Using TAMP with RenovoCath in Oncology Management
How Hospitals are Using TAMP with RenovoCath in Oncology Management* Visit https://ir.renovorx.com/news-events/clinical-news to Learn More NBC News highlighted the potential of RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, designed for targeted drug-delivery via the RenovoCath d
Slide 30: Thank You
Thank You Investor Relations Contact: KCSA Strategic Communications Valter Pinto or Jack Perkins | RenovoRx@KCSA.com +1.212.896.1254 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT